Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new ...

Changing one's own perspective and seeing value in one's self were some pieces of advice Chris Ruden had for attendees of the University of North Dakota's Disability Awareness ...

Collaborative research is underway to translate scientific discovery into actionable evidence ...

The latest PV Reliability Workshop highlighted why investing in PV reliability and quality is more important than ever.

Stranger Things: The Complete Series is coming to 4K/Blu-ray, and is one of the few Netflix shows to get the physical media treatment. Get the details here.

Presentations among children with multiple food allergies vary by allergen combination, indicating distinct phenotypes, ...

Does HTC-19 have an identity that is distinct from that of other chromatography conferences? A: The HTC conference traditionally attracts a relatively large number of participa ...

New panel expands coverage for Alzheimer's and Parkinson's diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and 12 assays ...

New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript March 17, 2026 Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.09657.